When looking at different healthcare interventions for a disease, there may be limited direct evidence on how the treatments compare with each other in terms of their efficacy, tolerability or another measure of interest.
In this video, EVERSANA’s Chris Drudge, MPH, PhD, Associate Project Manager – Value and Evidence, shares how indirect treatment comparisons (ITCs) can be used to fill in the blanks and compare treatments that have not yet been directly compared in a randomized clinical trial. However, ITC feasibility assessments (FAs) are also necessary to understand whether ITC is suitable and, if so, which ITC method(s) are most appropriate.
Watch the full video here:
Assessing the Feasibility of Indirect Treatment Comparisons
EVERSANA employs a team of over 6000 professionals across 40+ locations around the world. From industry-leading patient service and adherence support to global pricing and revenue management, our team informs the strategies that matter…